Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein  by Han, Dong P et al.
www.elsevier.com/locate/yviro
Virology 326 (2004) 140–149Development of a safe neutralization assay for SARS-CoV and
characterization of S-glycoprotein
Dong P. Han,a Hyung G. Kim,a Young B. Kim,a,1 Leo L.M. Poon,b and Michael W. Choa,*
aDepartment of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
bDepartment of Microbiology, Queen Mary Hospital, University of Hong Kong, Hong Kong, ChinaReceived 19 March 2004; accepted 17 May 2004Abstract
The etiological agent of severe acute respiratory syndrome (SARS) has been identified as a novel coronavirus SARS-CoV. Similar to
other coronaviruses, spike (S)-glycoprotein of the virus interacts with a cellular receptor and mediates membrane fusion to allow viral entry
into susceptible target cells. Accordingly, S-protein plays an important role in virus infection cycle and is the primary target of neutralizing
antibodies. To begin to understand its biochemical and immunological properties, we expressed both full-length and ectodomain of the
protein in various primate cells. Our results show that the protein has an electrophoretic mobility of about 160–170 kDa. The protein is
glycosylated with high mannose and/or hybrid oligosaccharides, which account for approximately 30 kDa of the apparent protein mass. The
detection of S-protein by immunoassays was difficult using human convalescent sera, suggesting that the protein may not elicit strong
humoral immune response in virus-infected patients. We were able to pseudotype murine leukemia virus particles with S-protein and produce
SARS pseudoviruses. Pseudoviruses infected Vero E6 cells in a pH-independent manner and the infection could be specifically inhibited by
convalescent sera. Consistent with low levels of antibodies against S-protein, neutralizing activity was weak with 50% neutralization titers
ranging between 1:15 to 1:25. To facilitate quantifying pseudovirus-infected cells, which are stained blue with X-Gal, we devised an
automated procedure using an ELISPOT analyzer. The high-throughput capacity of this procedure and the safety of using SARS
pseudoviruses should make possible large-scale analyses of neutralizing antibody responses against SARS-CoV.
D 2004 Elsevier Inc. All rights reserved.Keywords: SARS; Neutralization assay; Pseudovirus; Glycosylation; Coronavirus; S-proteinal., 2003). With a mortality rate of over 9%, SARS-CoV hadIntroduction
During the first epidemic of severe acute respiratory
syndrome (SARS), which began in November of 2002 in
Guandong Province of the People’s Republic of China, and
lasted for about 7 months, close to 8100 people were
infected worldwide, among which 774 people died (WHO,
2003). The etiological agent of this atypical respiratory
disease has been identified as a novel coronavirus (desig-
nated as SARS-CoV) (Drosten et al., 2003; Fouchier et al.,
2003; Ksiazek et al., 2003; Peiris et al., 2003; Poutanen et0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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have been very few incidences of SARS infections during
the winter season of 2003–2004. However, with multiple
modes of virus transmission and a wide range of potential
nonhuman reservoirs including wild animals commonly
found in markets (e.g., civet cats and raccoon dogs; Guan
et al., 2003) as well as domestic cats (Martina et al., 2003),
it is highly likely that a virus of this nature will most
certainly resurface in the future. Currently, there are no
antiviral drugs, immunotherapeutic agents, or vaccines
available against the virus. To better control or prevent
future epidemics, anti-SARS-CoV drugs and/or vaccines
need to be developed.
SARS-CoV belongs to Coronaviridae family. The ge-
nomic organization of the virus is similar to that of other
coronaviruses with a general order of replicase (Rep; ORFs-
1a and 1b), spike (S)-glycoprotein, envelope (E), membrane
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(Marra et al., 2003; Rota et al., 2003) (Fig. 1). Several open-
reading frames have also been identified, which may encode
additional proteins (Marra et al., 2003; Rota et al., 2003;
Snijder et al., 2003). Their functions, however, are not
known at the present time. The protein of a major interest
as a target of antiviral drug development efforts as well as
for developing vaccines is S-glycoprotein. S-protein of
coronaviruses, which is thought to function as a trimer
(Delmas and Laude, 1990), is responsible for both binding
to cellular receptors and inducing membrane fusion for virus
entry into target cells (Collins et al., 1982; Godet et al.,
1994; Kubo et al., 1994). Mutations in the protein have been
shown to alter virulence and cellular tropism (Fazakerley et
al., 1992; Leparc-Goffart et al., 1998; Sanchez et al., 1999).
Taken together, the S-protein plays a critical role in the
biology and pathogenesis of coronaviruses. Not surprising-
ly, it is an important target of virus-neutralizing antibodies
(Chang et al., 2002; Collins et al., 1982; Fleming et al.,
1983; Godet et al., 1994; Kant et al., 1992; Kubo et al.,
1993, 1994; Takase-Yoden et al., 1991). Moreover, mice
immunized with a recombinant S-protein, or a peptide
derived from it, are protected from lethal challenges with
murine hepatitis virus (MHV) (Daniel and Talbot, 1990;
Koo et al., 1999).
S-protein is a type I membrane glycoprotein, which is
translated on membrane-bound polysomes, inserted into
rough endoplasmic reticulum (RER), cotranslationally gly-
cosylated, and transported to the Golgi complex. During the
transport, S-proteins are incorporated onto maturing virus
particles, which assemble and bud into a compartment that
lies between the RER and Golgi (Lai and Holmes, 2001).
Virions are carried from Golgi to plasma membrane in
secretory vesicles. Virions are released from cells when
virion-containing vesicles fuse with plasma membrane.
Excess S-proteins not incorporated onto virus particles are
transported to the surface of plasma membrane (Lai and
Holmes, 2001; Tsai et al., 1999; Yamada et al., 1998).
S-protein of SARS-CoV is 1255 amino acids long (Fig. 1).
It is predicted to have a 13 amino acid signal peptide at the
amino-terminus, a single ectodomain (1182 amino acids)
and a transmembrane region followed by a short cytoplas-
mic tail (28 residues) at the carboxy-terminus (Marra et al.,
2003; Rota et al., 2003). Due to low sequence homology
between the S-protein of SARS-CoV and that of the other
coronaviruses (Marra et al., 2003; Rota et al., 2003), the
structural and immunogenic properties of SARS-CoV S-
protein must be ascertained experimentally. The cellular
receptor for SARS-CoV has recently been identified to be
angiotensin-converting enzyme 2 (ACE2; Li et al., 2003).
The molecular interactions between the S-protein and ACE2
are not yet known. Better understanding of the interactions
could lead to development of virus entry inhibitors.
Neutralizing antibodies (Nabs) play a critical role in
protection against a variety of viral diseases. An accurate
assessment of Nab responses in virus-infected patients isneeded to determine immune correlates of protection. It is
also an essential and integral part of a vaccine development
process. Conventional virus-neutralization assays require
the use of replication-competent, infectious viruses. Evalu-
ating virus-neutralizing activity of a large number of anti-
sera with these assays is undesirable due to safety concerns,
especially for a biosafety level 3 (BSL3) pathogen like
SARS-CoV. The same safety concerns have prompted our
laboratory to utilize replication-defective pseudoviruses for
HIV-1 neutralization assay (Kim et al., 2001). In this assay,
nonreplicating Moloney murine leukemia virus (MuLV)
particles pseudotyped with HIV-1 envelope glycoproteins
are used (Schnierle et al., 1997). These pseudoviruses
encode a h-galactosidase gene, which allows detection of
individual infected cells when stained with X-Gal (5-bromo-
4-chloro-3-indolyl-h-D-galactopyranoside). In this study, we
report development of a SARS-CoV pseudovirus neutrali-
zation assay, which should be particularly valuable for
researchers who may not have easy access to BSL3 con-
tainment facility. Additionally, we describe a high-through-
put system for quantitative analyses of X-Gal stained cells.
This assay system should facilitate rapid evaluation of
antibody responses to vaccine candidates and/or entry
inhibitors against SARS-CoV.Results
Expression of SARS-CoV S-glycoprotein
To express SARS-CoV S-glycoprotein, we initially cloned
a DNA fragment encoding the protein into pcDNA-3 vector
(pcDNA-S; Fig. 1B). To detect S-protein, Western blot was
performed with convalescent sera from SARS-CoV-infected
patients. However, no clear protein band was detected despite
number of attempts. We reasoned that one of the possibilities
for the inability to detect the protein is a low level of S-protein
expressed from pcDNA-S. To increase the amount of S-
protein expressed, we subcloned the S gene into pHCMV-G
vector (Burns et al., 1993), which expresses high level of
vesicular stomatitis virus (VSV) G glycoprotein. Although
we were able to express higher amount of S-protein (see
below), this was not sufficient to detect a clear band on
Western blots. An alternative explanation is that anti-
bodies against the protein in convalescent sera cannot
recognize S-protein subjected to denaturing conditions of
SDS-PAGE (viz. linear epitopes). However, because
results from radioimmunoprecipitation and indirect immu-
nofluorescence assays were also ambiguous, it is most
likely that the antibody titer against S-protein is very low
in convalescent sera.
To further increase protein expression level, S gene was
subcloned into a pTM vector (Moss et al., 1990). With this
vector, a protein of interest is under the control of a strong
T7 RNA polymerase (T7RNAP) promoter and the protein is
expressed when cells transfected with the plasmid are
Fig. 1. Construction of SARS-CoV S glycoprotein expression vectors. (A) Genomic organization of SARS-CoV. Only the major nonstructural (replicase
ORF1a and 1b) and structural genes (S, E, M, and N) are illustrated. The signal peptide (SP) and transmembrane (TM) domains of the S-protein, and the
locations of 23 potential N-linked glycosylation sites, are indicated. Histidine-tagged ectodomain of S-protein is indicated as eS-His. (B) A cloning strategy for
expressing S glycoprotein. See Materials and methods for details.
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T7RNAP (vTF7-3; Fuerst et al., 1986). The presence of
encephalomyocarditis virus Internal Ribosome Entry Site
(IRES) at the 5V end of RNA transcripts allows efficient
translation of mRNA transcribed in cytoplasm. Using pTM-
S, we were able to detect a faint, but distinct band of
approximately 160–170 kDa by Western blot (Fig. 2A, lane
3). We also reevaluated pcDNA-S as this vector has a dual
promoter system (CMV and T7 promoter). Using T7 pro-
moter, we were able to detect a protein band of a similar
size, albeit less clear than using pTM-S (lane 2). The lower
expression of the protein is likely due to the lack of IRES in
the pcDNA vector.
Because the calculated molecular weight of S-protein
without 13 amino acid signal peptide is about 138 kDa, the
result suggested posttranslational modification (e.g., glyco-
sylation). To better demonstrate this, we generated another
clone (pTM-eSHis) that expresses the entire ectodomain of
S-protein (amino acids 1–1190) with a six-histidine tag at
the carboxy terminus. The ectodomain of S-protein migrated
with an approximate molecular weight of 163 kDa while its
calculated molecular weight is only 131.2 kDa (Fig. 2B,
lane 2). To demonstrate that this difference is due to
glycosylation, eSHis protein was treated with endoglycosi-
dase H (Endo-H) or peptide: N-glycosidase F (PNGase F).
As shown in Fig. 2B (lanes 3 and 4), treatment with either
glycosidase increased the mobility of the protein to approx-
imately 133 kDa. Because the mobility of the protein treated
with either glycosidases was the same, S-protein is most
likely modified with high mannose and/or hybrid, rather
than complex, oligosaccharides. While S-glycoprotein ofFig. 2. Analyses of SARS-CoV S-protein glycosylation. (A) HeLa cells
transfected with either pcDNA (empty vector), pcDNA-S, or pTM-S were
infected with vTF7-3. S-protein (triangle) was detected by Western blot
using convalescent sera. Vaccinia-virus-specific bands are indicated by VV.
Ten percent acrylamide gel was used. (B) Histidine-tagged ectodomain of
S-protein expressed in HeLa cells was either untreated (lane 2) or treated
with Endo-H or PNGaseF glycosidases (lanes 3 and 4, respectively). The
protein was detected by Western blot with anti-6His antibody. No band
was detected from cells transfected with an empty vector (lane 1).
Acrylamide gradient gel (4–12%) was used.some coronaviruses is cleaved into two subdomains, S1 and
S2, the fact that we observed only a single band suggests
that SARS-CoV S-protein functions as a single unit.
Production and characterization of SARS-CoV
pseudoviruses
Despite difficulties in detecting S-protein directly by
immunoassays, proteins expressed from both pcDNA-S
and pHCMV-S constructs were able to pseudotype MuLV
particles to produce SARS pseudoviruses that could readily
infect Vero E6 cells (Fig. 3A). None of the other cell lines
we tested, including HeLa, A549, 293T, and BS-C-1, were
susceptible. This is in contrast to VSV-G pseudotyped
viruses, which could infect all cell lines (data not shown).
The fact that BS-C-1 cells, which, like Vero E6 cells, are
African green monkey kidney cells, were not susceptible
was somewhat unexpected. However, when we performed
infections with a high multiplicity of infection, we were able
to detect infected BS-C-1, albeit at a significantly reduced
titer (7–8-fold compared to Vero E6 cells; data not shown).
This result was not too surprising because it has been shown
that even 293T cells, which express small amounts of
ACE2, support some basal level of SARS-CoV replication
(Li et al., 2003).
Many pseudovirus-infected cells appeared as a doublet,
which is the result of a cell division following integration of
MuLV pseudovirus genome encoding h-galactosidase.
These doublets are counted as a single infectious unit. A
typical yield of SARS pseudoviruses was about 2  104
infectious units per milliliter of culture supernatant using
pHCMV-S, which was about fivefold greater than using
pcDNA-3. This yield is comparable to what we have been
able to achieve for HIV-1 pseudoviruses (between 2  103
and 2  104 depending on envelopes; Kim et al., 2001), but
lower than VSV-G pseudovirus yield (between 3  104 and
9  104 depending on target cell lines used). Interestingly,
SARS pseudovirus production was about 20-fold less effi-
cient when plasmid transfection was performed by calcium
phosphate method compared with using cationic lipids
(lipofection). This difference, however, was not observed
for VSV-G pseudovirus production. An additional differ-
ence was that a longer incubation time was needed to
achieve peak pseudovirus production for SARS-S compared
to VSV-G (3 vs. 2 days posttransfection, respectively). The
reasons for these discordant results are unknown at the
present time.
Cellular entry of coronaviruses can occur either by acidic
pH-dependent or -independent pathway (Gallagher et al.,
1991; Lai and Holmes, 2001; Li and Cavanagh, 1990, 1992;
Nash and Buchmeier, 1997; Payne et al., 1990). To inves-
tigate whether SARS-CoV infection requires low pH, we
examined sensitivity of pseudovirus infections to lysosomo-
tropic agents chloroquine and NH4Cl. As expected, infec-
tivity of viruses pseudotyped with VSV-G was reduced
by chloroquine and NH4Cl in a dose-dependent manner
Fig. 3. SARS-CoV pseudovirus infection. (A) Infectivity of SARS pseudoviruses in Vero E6 cells. Infected cells are stained with X-Gal. Mock-infected cells
are shown on the top. Infectivity of SARS pseudoviruses was unaffected by lysosomotropic agents chloroquine (B) and by NIH4Cl (C). In contrast, VSV-G
pseudovirus infection was inhibited by both agents.
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rus infection was virtually unaffected, suggesting that
SARS-CoV infection proceeds in an acidic pH-independent
manner.
Neutralization assay
To assess whether SARS pseudoviruses we generated
could be used to quantify virus-neutralizing antibodies, we
examined their susceptibility to convalescent sera from
SARS-CoV-infected patients. As shown in Fig. 4A, sera
from two patients were able to specifically neutralize SARS
pseudoviruses; the same convalescent sera could not neu-Fig. 4. Pseudovirus neutralization assay. (A) Three different pseudoviruses (HIV
convalescent sera from patients 703497 and 56053 (1:5 dilution). Neutralizing ac
patients against SARS pseudovirus. HIV-1 pseudovirus infection was done with HO
done with Vero E6 cells. (B) Titration of neutralizing antibodies. Convalescent se
neutralizing activity. Approximately 70 infectious units were used.tralize HIV-1 or VSV-G pseudoviruses and no neutralizing
activity was observed with a normal serum. To determine
neutralizing antibody titers in virus-infected patients, we
performed the assay with serially diluted sera from seven
patients. As shown in Fig. 4B, antibody levels were quite
similar in all patients with 50% neutralization titer between
1:15 and 1:25.
High-throughput quantification of pseudovirus infections
Although the pseudovirus neutralization assay is sensi-
tive, quantitative, and safe, it has one disadvantage of
having to count individual X-Gal-stained cells through a1, VSV-G, and SARS-S) were incubated with either normal serum, or two
tivity was observed only from convalescent sera from SARS-CoV-infected
S-CCR5-CD4 cells while VSV-G and SARS-S pseudovirus infections were
ra from seven different SARS-CoV patients were used to titer pseudovirus-
Fig. 5. Automation of counting pseudovirus-infected cells using an ELISPOT reader. HOS cells were infected with twofold serially diluted pseudovirus (10–
0.625 Al inoculum) in duplicate, in 96-well plate. MuLV pseudotyped with VSV-G was used. (A) Images of wells infected with five different dilutions of
pseudovirus, in duplicate. (B) A magnified image of the boxed well. (C) The number of infectious foci is plotted as a function of virus inoculum.
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possibility of automating the data collection procedure using
an ELISPOT reader (ImmunoSpot Analyzer, Cellular Tech-
nology Ltd.). Although this instrument is commonly used to
quantify antigen-specific T cell cytokine responses by
counting chromogenic immunospots (e.g., IFN-g), we ra-
tionalized that it might be able detect X-Gal-stained blue
cells. As shown in Fig. 5, there was no problem with using
the instrument to count spots at a single-cell resolution and
the analysis was highly efficient as the entire 96-well plate
could be processed in less than 20 min. Virus-infected cells
appearing as doublets did not pose a problem because
parameters on the analysis software could be adjusted to
count two stained cells adjacent to each other as one. The
number of infectious foci counted was quite linear as a
function of virus inoculum (Fig. 5C), validating the meth-
odology. This procedure could be used to quantify other
assays based on X-Gal staining of cells (e.g., recombinant
vaccinia viruses that express h-galactosidase).Discussion
In this study, we expressed SARS-CoV S-glycoprotein,
which was able to pseudotype MuLV particles. SARS
pseudoviruses were able to efficiently infect Vero E6 cells,
which have been shown to support SARS-CoV infection.
The infection did not require low pH, suggesting viral
entry is mediated by a direct fusion event between viral
and plasma membranes. This result is consistent with a
previous report that cell-to-cell fusion mediated by S-
protein and its cellular receptor ACE2 occurred at neutral
pH (Xiao et al., 2003). However, our result is in direct
disagreement with recently published article by Simmons
et al. (2004). There are three major differences in exper-imental procedures between the two studies. First, we
pseudotyped MuLV particles whereas Simmons et al. used
HIV-1. Second, we used an authentic S-glycoprotein
whereas they used a C-terminal fusion protein that includ-
ed a V5 epitope and polyhistidine tag, which totaled, by
our estimation, 27 extra amino acids. Whether the discrep-
ant result is due to the use of different S-glycoproteins
and/or different virus cores needs to be further investigat-
ed. The third difference between the studies is the con-
centrations of lysosomotropic agents used. While we used
NH4Cl at 0–50 AM amounts, which are sufficient to
inhibit VSV-G-mediated fusion (Fig. 3; Picard-Maureau
et al., 2003), they used millimolar (mM) amounts. At these
concentrations, NH4Cl could have a secondary effect on S-
glycoprotein. We were unable to find concentrations of
chloroquine used in their study. It is interesting to note
that while Simmons et al. observed that pseudovirus
infections required low pH, S-protein-mediated cell-to-cell
fusion did not.
The SARS pseudoviruses we generated could be specif-
ically inhibited by convalescent sera from SARS-CoV
infected patients, indicating that S-glycoprotein of SARS-
CoV is a target of neutralizing antibodies as it is for other
coronaviruses. The major purpose of generating SARS
pseudoviruses was to devise an assay system to assess
virus-neutralizing antibodies safely and rapidly without
having to use infectious, replication-competent SARS-CoV.
The results of our study indicate that SARS pseudoviruses
could be used to evaluate efficacy of various S-glycopro-
tein-based vaccine candidates to elicit virus-neutralizing
antibodies. They could also be used to perform structure–
function analyses of S-glycoprotein. Due to a large size of
SARS-CoV genome, it would be difficult to perform such
analyses directly in the context of the virus, not to mention
potential safety hazards from working with it. In contrast,
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readily using pseudoviruses.
Our attempt to characterize biochemical and immuno-
logical properties of the S-protein was hampered by the fact
that antibody titers against the protein in convalescent sera
were extremely low; we were able to identify only a faint
band on a Western blot (with high background) and attempts
to detect the protein by immunofluorescence and radio-
immunoprecipitation assays were less than successful. In
contrast, convalescent sera have been successfully used to
detect SARS-CoV-infected cells by an immunofluorescence
assay (Hsueh et al., 2003; Peiris et al., 2003). Together, the
available data seem to suggest that S-protein might not be
immunogenic, at least compared to other viral proteins. In
fact, immunoreactivity analyses of a panel of synthetic
peptides derived from S, membrane (M), and nucleocapsid
(N) proteins suggested that N protein might be the most
immunogenic protein (Wang et al., 2003).
The nonimmunogenic nature of S-protein might present
potential problems in developing a vaccine that can elicit
potent neutralizing antibodies against SARS-CoV. In this
regard, it is interesting to note that S-protein is highly
glycosylated with 23 potential asparagine-linked glycosyla-
tion sites. Based on our analyses of the ectodomain of the
protein, carbohydrate residues account for approximately 30
kDa (based on mobility in SDS-PAGE). The glycans were
primarily high mannose and/or hybrid type. This, however,
needs to be verified using proteins produced from non-
vaccinia virus expression system, because the virus infec-
tion could possibly affect cellular glycosylation machinery.
Extensive glycosylation of HIV-1 envelope glycoprotein has
been one of the major obstacles in eliciting good humoral
responses against the protein and in developing an effective
vaccine against the virus (Cho, 2003). It remains to be seen
whether and to what extent glycans on S-protein affect
immunogenic properties of the protein. Interestingly, poten-
tial glycosylation sites are clustered into three regions of the
protein (Fig. 1A): N-terminal, middle, and C-terminal. It has
been shown that individual glycosylation sites on HIV-1
surface glycoprotein gp120 may have different functions;
while some are important for evading immune responses,
others are critical for maintaining proper protein structure
necessary to interact with cellular receptors and mediate
membrane fusion (Ogert et al., 2001; Reitter et al., 1998).
Additional studies are needed to determine whether glyco-
sylation sites in different clusters of S-protein serve different
functions.
In the absence of an effective vaccine and/or antiviral
drugs against SARS-CoV, early detection of virus-infected
patients would be critical for effective containment of future
epidemics. Quantitative RT-PCR-based diagnostic assays
have been described for SARS-CoV (Grant et al., 2003;
Lau et al., 2003; Ng et al., 2003; Poon et al., 2003a, 2003b;
Tang et al., 2004; Yam et al., 2003). Despite high sensitivity,
their utility has some limitations: (i) the detection rate varies
widely between 20% and 80% depending on clinical sam-ples and protocols used for the assay; (ii) the window of
detectability is limited to early stages of infection; and (iii)
the assay is not suitable for routine surveillance. Antibodies
against SARS proteins have been shown to appear as early
as 9 days after the onset of illness (Hsueh et al., 2003).
Therefore, development of a high-throughput serology-
based diagnostics could complement PCR-based assays. In
this regard, a virus-neutralization assay could be used as a
confirmatory test, which would enhance the accuracy of
early diagnosis of SARS-CoV. Because neutralizing anti-
bodies are important for virus clearance, the assay could
also be used to assess disease prognosis. In either case, the
availability of SARS pseudoviruses allows avoiding the use
of infectious SARS-CoV.Materials and methods
Construction of S-glycoprotein expression vectors
The overall cloning strategy is shown in Fig. 1B. Two
parental plasmids encoding a SARS-CoV S gene (Urbani
strain), pENTR-S and pCR-S, were obtained from the U.S.
Centers for Disease Control and Prevention. Two S-protein-
expressing plasmids (pcDNA-S* and pcDNA-S) were gen-
erated using pcDNA-3 (Invitrogen). The S gene in pcDNA-
S*, which was transferred from pENTR-S (BamHI–EcoRI
fragment), lacks the original translation stop codon TAA
because it was changed to AAT of EcoRI restriction site
(gAATtc). pcDNA-S with a stop codon was constructed by
replacing a SwaI–EcoRI fragment of pcDNA-S* with the
same fragment from pCR-S. To generate pHCMV-S, a
BamHI–EcoRI fragment from pcDNA-S was inserted into
a BamHI site of pHCMV-G following blunting ends with
Klenow. To construct pTM-S, a BamHI–XhoI fragment
from pcDNA-S was cloned into the corresponding sites of
pTM–NdeI (Cho et al., 1994). Despite the fact that pTM-S
has a small open-reading frame that encodes eight amino
acids between the Internal Ribosome Entry Site of pTM-
NdeI vector and the S gene, S-protein was efficiently
expressed and the plasmid was used as is without further
modification. To generate pTM-eSHis, 3V end of the ecto-
domain was PCR amplified using a sense primer 5V-GTC
GTC AAC ATT CAA AAA GAA-3V (nts 3472–3492 of S
gene) and an antisense primer 5V-AAT GAA GCG GAT
CCCGGGTTA GTG ATG GTG GTG ATG ATG TTG CTC
ATA TTT TCC CAA-3V. Base-pairing region (nts 3553–
3570) is shown in bold and the six histidine residues are
italicized. The amplified fragment was digested with SwaI
(nt 3521) and SmaI (underlined) and subsequently cloned
into pTM-S digested with SwaI and StuI.
Cell culture, protein expression, and Western blots
All cell lines, except for Vero E6, were maintained in
DMEM supplemented with 10% fetal bovine serum (FBS),
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Vero E6 cells were maintained in EMEM with the same
supplements plus 0.1 mM nonessential amino acids. Cells
were cultured at 37 jC in 5% CO2 incubators. To express S-
protein, cells were transfected with plasmids by a calcium
phosphate precipitation method. Briefly, 0.5 ml of 0.25 M
CaCl2 solution containing 30 Ag of plasmids was slowly
mixed with 2 HBS (50 mM HEPES, 1.5 mM Na2HPO4,
280 mM NaCl, pH 7.1) and the mixture was added to cells.
After an overnight incubation, culture medium was replaced
and cells were further incubated for two additional days. For
expression from pTM-S and pTM-eSHis, transfected cells
were infected with vTF7-3 (Fuerst et al., 1986) at a
multiplicity of infection of 5. Following 2 days of infection,
cells were lysed with a hypotonic cell lysis buffer (10 mM
Tris, pH 8.0, 10 mM NaCl, 1.5 mM MgCl2, 1% NP-40).
Insoluble cell debris and nuclei were removed by a brief
centrifugation in a microfuge. Cell lysates were subjected to
SDS-PAGE and Western blot. S-proteins were detected with
either a pool of convalescent sera (1:100 dilution) or anti-
His (C-terminal) monoclonal antibody (Invitrogen; 1:3000
dilution) followed by horseradish peroxidase-conjugated
goat anti-human or anti-mouse IgG antibody (Pierce), re-
spectively. Protein bands were visualized using SuperSignal
West Pico Chemiluminescence detection system (Pierce).
Molecular weights of the protein bands were approximated
by the mobility of standard molecular weight markers.
Production of pseudoviruses and infection analyses
Pseudoviruses were generated as previously described
(Kim et al., 2001). Briefly, MuLV packaging cell line
TELCeB6 (Schnierle et al., 1997) was transfected with
pcDNA-S, pHCMV-S, pHCMV-G (Burns et al., 1993), or
pLTR-gp140 (HIV-1DH12; Kim et al., 2001) using either
calcium phosphate precipitation or lipofection (Lipofectin;
Invitrogen) method. Two days posttransfection (3 days for
SARS pseudovirus), cell culture medium was harvested and
subjected to centrifugation (1700  g, 10 min) to remove
cell debris. Supernatant was aliquoted, stored at 80 jC and
used as a virus stock.
Virus titer was determined in Vero E6 cells for SARS-S
and VSV-G or in HOS-CD4-CCR5 (Cheng-Mayer et al.,
1997; Deng et al., 1996) for HIV-1 gp140 pseudotyped
viruses. Typically, cells were infected with 60–80 infectious
units for 36 h. Cells were washed with PBS and incubated
with a fixative (1% formaldehyde, 0.05% glutaraldehyde in
PBS) for 10 min at room temperature. The cells were
washed twice with PBS and incubated with a freshly
prepared staining solution (PBS containing 5 mM potassium
ferricyanide, 5 mM potassium ferrocyanide, 2 mM magne-
sium chloride, and 1 mg/ml of X-Gal) for >2 h at 37 jC. For
routine analyses, X-Gal-stained blue cells were manually
counted using an inverted microscope.
To determine pH-dependency of viral entry, Vero E6 cells
were incubated in culture medium containing 0–100 AMchloroquine for 1 h at 37 jC before adding viruses. VSV-G
or SARS-S pseudoviruses were allowed to adsorb to cells
for 1 h at 37 jC in the absence of chloroquine. Following
adsorption, virus inoculum was removed, cells were
washed, and infection was allowed to proceed for about
36 h in the absence of chloroquine. For NH4Cl, cells were
incubated with 0–50 AM. Due to minimal cytotoxicity,
NH4Cl was present throughout the infection period includ-
ing 1 h incubation before virus addition. All infections were
done in duplicates.
Neutralization assay was performed as previously de-
scribed (Kim et al., 2001) using convalescent sera (13–50
days post-onset of symptoms) obtained from CDC or from
patients hospitalized in Queen Mary Hospital, Hong Kong.
Approximately 60–80 infectious units of pseudoviruses
were incubated with serially diluted, heat-inactivated (56
jC, 30 min) convalescent or normal sera for 1 h at 37 jC.
The mixture was subsequently added to Vero E6 (for SARS-
S or VSV-G) or HOS-CD4/CCR5 (for HIV-1 gp140) cells.
Virus infection was allowed to proceed for another 36 h.
Virus-neutralizing activity was determined relative to no
serum control.
Automation of quantifying pseudovirus infection
The general pseudovirus infection procedure is the same
as described above. The major difference was that 96-well
plates with a white membrane bottom normally used for
ELISPOT assays (Plate M200; BD Biosciences) were uti-
lized rather than regular tissue culture plates. ImmunoSpot
Analyzer from Cellular Technology Ltd. was used as per
manufacturer’s recommendations.Acknowledgments
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